Reuters logo
AstraZeneca's diabetes drug Xigduo approved in Europe
January 22, 2014 / 7:30 AM / in 4 years

AstraZeneca's diabetes drug Xigduo approved in Europe

LONDON, Jan 22 (Reuters) - AstraZeneca said European regulators had approved Xigduo for type 2 diabetes, in what was the first green light for a fixed dose combination of a SGLT2 inhibitor and metformin.

The drug combines in a twice daily tablet Forxiga, a SGLT2 inhibitor that reduces the reabsorption of excess glucose, and metformin, a standard in treating the condition.

Xigduo was developed by the alliance in diabetes therapy between the British company and Bristol-Myers Squibb, the companies said on Wednesday. AstraZeneca will take full control of the unit later this quarter.

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below